SG11202009831UA - Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof - Google Patents
Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereofInfo
- Publication number
- SG11202009831UA SG11202009831UA SG11202009831UA SG11202009831UA SG11202009831UA SG 11202009831U A SG11202009831U A SG 11202009831UA SG 11202009831U A SG11202009831U A SG 11202009831UA SG 11202009831U A SG11202009831U A SG 11202009831UA SG 11202009831U A SG11202009831U A SG 11202009831UA
- Authority
- SG
- Singapore
- Prior art keywords
- nrg
- methods
- fusion protein
- recombinant fusion
- protein compositions
- Prior art date
Links
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 102000055650 human NRG1 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656246P | 2018-04-11 | 2018-04-11 | |
| PCT/US2019/026889 WO2019200033A1 (en) | 2018-04-11 | 2019-04-11 | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009831UA true SG11202009831UA (en) | 2020-11-27 |
Family
ID=66484143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009831UA SG11202009831UA (en) | 2018-04-11 | 2019-04-11 | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11046741B2 (en) |
| EP (2) | EP4361177A2 (en) |
| JP (2) | JP2021535727A (en) |
| KR (1) | KR20210022542A (en) |
| CN (1) | CN113166218A (en) |
| AU (2) | AU2019252262B2 (en) |
| BR (1) | BR112020020646A2 (en) |
| CA (1) | CA3096420A1 (en) |
| CL (1) | CL2020002621A1 (en) |
| CO (1) | CO2020012621A2 (en) |
| EA (1) | EA202092458A1 (en) |
| IL (1) | IL277790A (en) |
| MX (1) | MX2020010740A (en) |
| PE (1) | PE20210111A1 (en) |
| PH (1) | PH12020551648A1 (en) |
| SG (1) | SG11202009831UA (en) |
| WO (1) | WO2019200033A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092458A1 (en) | 2018-04-11 | 2021-02-08 | Салюбрис Байотерапьютикс, Инк. | COMPOSITIONS BASED ON RECOMBINANT FUSED PROTEIN CONTAINING HUMAN NEUREGULIN-1 (NRG-1), AND METHODS FOR THEIR APPLICATION |
| AR121035A1 (en) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | NEUREGULIN-4 COMPOUNDS AND METHODS OF USE |
| US20230057622A1 (en) * | 2019-09-16 | 2023-02-23 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant Human Neuregulin Derivatives and Use Thereof |
| TW202400217A (en) * | 2022-03-15 | 2024-01-01 | 美商信立泰生物醫藥公司 | Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| AU2002304965A1 (en) * | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| JP4955548B2 (en) | 2004-07-09 | 2012-06-20 | ウェイン・ステイト・ユニバーシティ | Hybrid protein with ErbB4 extracellular domain and neuregulin heparin binding domain for targeting |
| US8053569B2 (en) * | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| US20070213264A1 (en) * | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| WO2009052184A2 (en) | 2007-10-16 | 2009-04-23 | Receptor Biologix, Inc. | Compositions comprising optimized her1 and her3 multimers and methods of use thereof |
| US20090226435A1 (en) * | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| WO2010006059A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
| JP5743898B2 (en) | 2008-11-28 | 2015-07-01 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | Neuregulin peptide and use thereof |
| CA2775573A1 (en) * | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
| CN102139095A (en) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | Method for applying neuregulin to prevent, treat or delay cardiac ischemia reperfusion injuries, and composition for preventing, treating or delaying cardiac ischemia reperfusion injuries |
| WO2011119836A1 (en) * | 2010-03-24 | 2011-09-29 | Massachusetts Institute Of Technology | Methods and compositions for cardioprotection and cardioregeneration |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| US10196455B2 (en) * | 2013-11-07 | 2019-02-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neuregulin allosteric anti-HER3 antibody |
| CN104758922A (en) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | Formula for neuregulin preparation |
| EP3789042A1 (en) | 2014-04-10 | 2021-03-10 | Daiichi Sankyo Company, Limited | Method for producing anti-her3 antibody-drug conjugate |
| US10526416B2 (en) * | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| CN111407882A (en) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | Methods and compositions of neuregulin for preventing, treating, or delaying heart failure with preserved ejection fraction |
| CN109195993B (en) | 2016-02-06 | 2022-05-10 | 岸迈生物科技有限公司 | Tandem FAB immunoglobulins and uses thereof |
| JP7203426B2 (en) | 2016-09-15 | 2023-01-13 | ウニヴェルズィテート シュトゥットガルト | Antigen binding protein for HER3 |
| EA202092458A1 (en) | 2018-04-11 | 2021-02-08 | Салюбрис Байотерапьютикс, Инк. | COMPOSITIONS BASED ON RECOMBINANT FUSED PROTEIN CONTAINING HUMAN NEUREGULIN-1 (NRG-1), AND METHODS FOR THEIR APPLICATION |
-
2019
- 2019-04-11 EA EA202092458A patent/EA202092458A1/en unknown
- 2019-04-11 CN CN201980025049.3A patent/CN113166218A/en active Pending
- 2019-04-11 SG SG11202009831UA patent/SG11202009831UA/en unknown
- 2019-04-11 EP EP24161673.9A patent/EP4361177A2/en active Pending
- 2019-04-11 PE PE2020001553A patent/PE20210111A1/en unknown
- 2019-04-11 MX MX2020010740A patent/MX2020010740A/en unknown
- 2019-04-11 CA CA3096420A patent/CA3096420A1/en active Pending
- 2019-04-11 KR KR1020207032449A patent/KR20210022542A/en unknown
- 2019-04-11 WO PCT/US2019/026889 patent/WO2019200033A1/en active Application Filing
- 2019-04-11 JP JP2020556258A patent/JP2021535727A/en active Pending
- 2019-04-11 BR BR112020020646-6A patent/BR112020020646A2/en unknown
- 2019-04-11 US US16/381,206 patent/US11046741B2/en active Active
- 2019-04-11 EP EP19723548.4A patent/EP3774859B1/en active Active
- 2019-04-11 AU AU2019252262A patent/AU2019252262B2/en active Active
-
2020
- 2020-10-02 PH PH12020551648A patent/PH12020551648A1/en unknown
- 2020-10-05 IL IL277790A patent/IL277790A/en unknown
- 2020-10-09 CL CL2020002621A patent/CL2020002621A1/en unknown
- 2020-10-21 CO CONC2020/0012621A patent/CO2020012621A2/en unknown
-
2021
- 2021-05-21 US US17/327,494 patent/US11718652B2/en active Active
-
2023
- 2023-06-13 US US18/333,797 patent/US20230322877A1/en active Pending
- 2023-06-14 JP JP2023097663A patent/JP2023134436A/en active Pending
- 2023-12-20 AU AU2023285793A patent/AU2023285793A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210022542A (en) | 2021-03-03 |
| PH12020551648A1 (en) | 2021-07-26 |
| EP4361177A2 (en) | 2024-05-01 |
| CA3096420A1 (en) | 2019-10-17 |
| WO2019200033A1 (en) | 2019-10-17 |
| AU2019252262A1 (en) | 2020-10-22 |
| MX2020010740A (en) | 2021-01-20 |
| BR112020020646A2 (en) | 2021-02-23 |
| EP3774859A1 (en) | 2021-02-17 |
| TW201945389A (en) | 2019-12-01 |
| US11718652B2 (en) | 2023-08-08 |
| US20230322877A1 (en) | 2023-10-12 |
| EP3774859B1 (en) | 2024-03-13 |
| AU2019252262B2 (en) | 2023-10-05 |
| US20200010522A1 (en) | 2020-01-09 |
| US11046741B2 (en) | 2021-06-29 |
| JP2023134436A (en) | 2023-09-27 |
| EA202092458A1 (en) | 2021-02-08 |
| IL277790A (en) | 2020-11-30 |
| US20210347841A1 (en) | 2021-11-11 |
| CN113166218A (en) | 2021-07-23 |
| CO2020012621A2 (en) | 2020-12-21 |
| PE20210111A1 (en) | 2021-01-19 |
| AU2023285793A1 (en) | 2024-01-18 |
| CL2020002621A1 (en) | 2021-06-11 |
| JP2021535727A (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277790A (en) | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof | |
| GB2595606B (en) | CRISPR-Cas effector polypeptides and methods of use thereof | |
| IL287273A (en) | Recombinant polyclonal proteins and methods of use thereof | |
| IL279510A (en) | Progranulin-fc polypeptide fusion proteins and uses thereof | |
| IL310398A (en) | Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof | |
| IL280102A (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
| IL275779A (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
| MX2021006017A (en) | Methods and compositions for treatment of disorders with follistatin polypeptides. | |
| EP3878461A4 (en) | TGF-ß RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL280103A (en) | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof | |
| SG11202006259SA (en) | Il-22 fc fusion proteins and methods of use | |
| IL282205A (en) | Disulfide bond stabilized polypeptide compositions and methods of use | |
| IL284670A (en) | Skin renewing and healing mixture of peptide components and its use | |
| EP4081533A4 (en) | Crispr-cas effector polypeptides and methods of use thereof | |
| SG11202110400QA (en) | Fusion protein and use thereof | |
| SG11202104912SA (en) | Fusion protein and use thereof | |
| EP3778629A4 (en) | Use of ryr2 protein or ryr2 recombinant protein in preparing anti-heart failure medicine | |
| ZA202101260B (en) | Long-acting recombinant glp1-fc-cd47 protein, preparation method and use thereof | |
| IL283830A (en) | Multigene construct for immune-modulatory protein expression and methods of use | |
| EP3816181A4 (en) | Improved fviii fusion protein and use thereof | |
| SG11202006726UA (en) | Recombinant vaccinia virus and pharmaceutical composition comprising same | |
| GB202201004D0 (en) | Reconbinant fusion polypeptide and use thereof | |
| EP3892729A4 (en) | Recombinant porcine parvovirus antigenic protein and use thereof | |
| EP3663313A4 (en) | N-terminal recombinant protein of ccr4 and usage thereof |